Mirae Asset Global Investments Co. Ltd. Increases Stock Holdings in GH Research PLC (NASDAQ:GHRS)

Mirae Asset Global Investments Co. Ltd. boosted its position in GH Research PLC (NASDAQ:GHRS) by 14.6% during the 4th quarter, HoldingsChannel reports. The firm owned 106,363 shares of the company’s stock after purchasing an additional 13,579 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in GH Research were worth $617,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. RTW Investments LP raised its stake in shares of GH Research by 53.4% in the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after buying an additional 1,158,172 shares during the period. Lynx1 Capital Management LP raised its stake in shares of GH Research by 13.8% in the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after buying an additional 133,804 shares during the period. Barclays PLC raised its stake in shares of GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after buying an additional 31,500 shares during the period. Finally, PEAK6 Investments LLC raised its stake in shares of GH Research by 72.9% in the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after buying an additional 16,991 shares during the period. 56.90% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on GHRS shares. JMP Securities decreased their price objective on GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday, March 1st. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a research note on Monday, March 4th.

GH Research Trading Down 5.2 %

Shares of GHRS opened at $10.50 on Friday. The business’s 50 day moving average is $9.97 and its 200 day moving average is $7.88. The company has a market capitalization of $546.32 million, a PE ratio of -15.44 and a beta of 0.84. GH Research PLC has a 12-month low of $5.05 and a 12-month high of $14.64.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Equities research analysts predict that GH Research PLC will post -0.96 earnings per share for the current year.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).